Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
Foghorn Therapeutics (NASDAQ: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO Adrian Gottschalk will present in a fireside chat on May 7 at 9:30 a.m. EST and participate in one-on-one meetings throughout the day. The company's Gene Traffic Control® platform primarily targets oncology applications and aims to develop treatments for a broad spectrum of diseases.
Foghorn Therapeutics (NASDAQ: FHTX), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di farmaci che correggono l'espressione genica anomala, ha annunciato la sua partecipazione alla prossima Citizens Life Sciences Conference che si terrà a New York il 7 e 8 maggio 2025. L'amministratore delegato Adrian Gottschalk terrà un intervento in formato fireside chat il 7 maggio alle 9:30 EST e parteciperà a incontri individuali durante tutta la giornata. La piattaforma Gene Traffic Control® dell'azienda è principalmente rivolta ad applicazioni oncologiche e mira a sviluppare trattamenti per un ampio spettro di malattie.
Foghorn Therapeutics (NASDAQ: FHTX), una empresa biotecnológica en etapa clínica enfocada en desarrollar medicamentos que corrigen la expresión genética anormal, anunció su participación en la próxima Citizens Life Sciences Conference en Nueva York los días 7 y 8 de mayo de 2025. El CEO Adrian Gottschalk presentará en una charla informal el 7 de mayo a las 9:30 a.m. EST y participará en reuniones uno a uno durante todo el día. La plataforma Gene Traffic Control® de la compañía está dirigida principalmente a aplicaciones oncológicas y busca desarrollar tratamientos para una amplia gama de enfermedades.
Foghorn Therapeutics (NASDAQ: FHTX)는 비정상적인 유전자 발현을 교정하는 약물 개발에 중점을 둔 임상 단계의 바이오테크 회사로, 2025년 5월 7일부터 8일까지 뉴욕에서 열리는 Citizens Life Sciences Conference에 참여한다고 발표했습니다. CEO Adrian Gottschalk는 5월 7일 오전 9시 30분(EST)에 파이어사이드 채팅에서 발표를 진행하며, 하루 종일 일대일 미팅에도 참석할 예정입니다. 회사의 Gene Traffic Control® 플랫폼은 주로 종양학 분야에 초점을 맞추고 있으며, 다양한 질병에 대한 치료법 개발을 목표로 하고 있습니다.
Foghorn Therapeutics (NASDAQ : FHTX), une société biotechnologique en phase clinique spécialisée dans le développement de médicaments corrigeant l'expression génétique anormale, a annoncé sa participation à la prochaine Citizens Life Sciences Conference qui se tiendra à New York les 7 et 8 mai 2025. Le PDG Adrian Gottschalk interviendra lors d'une discussion informelle le 7 mai à 9h30 EST et participera à des réunions individuelles tout au long de la journée. La plateforme Gene Traffic Control® de la société cible principalement des applications en oncologie et vise à développer des traitements pour un large éventail de maladies.
Foghorn Therapeutics (NASDAQ: FHTX), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Medikamenten zur Korrektur abnormaler Genexpression spezialisiert hat, gab seine Teilnahme an der bevorstehenden Citizens Life Sciences Conference in New York am 7. und 8. Mai 2025 bekannt. CEO Adrian Gottschalk wird am 7. Mai um 9:30 Uhr EST in einem Fireside-Chat sprechen und den ganzen Tag über an Einzelgesprächen teilnehmen. Die Gene Traffic Control®-Plattform des Unternehmens richtet sich hauptsächlich auf onkologische Anwendungen und hat zum Ziel, Therapien für ein breites Spektrum von Krankheiten zu entwickeln.
- None.
- None.
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Citizens Life Sciences Conference, being held May 7-8, 2025, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Fireside Chat Data and Time: Wednesday, May 7, 2025, at 9:30 a.m. EST
Presenter: Adrian Gottschalk, President and Chief Executive Officer
Management will also participate in one-on-one meetings on Wednesday, May 7, 2025.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. khellsvik@foghorntx.com
FAQ
When is Foghorn Therapeutics (FHTX) presenting at the Citizens Life Sciences Conference 2025?
Who will represent Foghorn Therapeutics (FHTX) at the Citizens Life Sciences Conference 2025?
What is Foghorn Therapeutics' (FHTX) main technology platform?
What is the primary therapeutic focus of Foghorn Therapeutics (FHTX)?
